Toshiki Etani

Papers

Total Citations

H-Index

About

Toshiki Etani is a clinical researcher focused on integrative oncology, with a particular emphasis on the role of natural compounds in prostate cancer management. His work bridges the gap between traditional pharmacology and modern cancer therapeutics, exploring how flavonoids like luteolin can serve as chemopreventive and chemotherapeutic agents. Etani’s most notable contribution is his 2025 study, "Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance," which has already garnered 4 citations in its early publication stage. This research addresses the critical clinical challenge of prostate cancer re-emergence following androgen deprivation therapy, offering preliminary evidence that luteolin may provide a safe, effective adjunct for patients on active surveillance. By investigating non-toxic dietary interventions, Etani’s work opens new avenues for managing cancer progression without the severe side effects of conventional treatments. His findings are particularly significant for patients seeking alternative or complementary strategies to delay disease advancement. As a rising voice in urological oncology, Etani continues to advance the understanding of how plant-based compounds can be integrated into standard care protocols, making his research highly relevant for clinicians and researchers exploring holistic cancer management approaches.